Evidence map›Paper›PMID 33208016›Full record

ArticleSLAS discovery : advancing life sciences R & D2021

Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines.

David A Close, John M Kirkwood, Ronald J Fecek, Walter J Storkus, Paul A Johnston

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in SLAS discovery : advancing life sciences R & D, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. PET Imaging of VLA-4 in a New BRAFMolecular imaging and biology · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

David A CloseDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
John M KirkwoodDepartments of Medicine, Dermatology, and Translational Science, and Melanoma and Skin Cancer Program, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
Ronald J FecekDepartment of Microbiology, Lake Erie College of Osteopathic Medicine at Seton Hill, Greensburg, PA, USA.
Walter J StorkusHillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Paul A JohnstonDepartment of Pharmaceutical Sciences, School of Pharmacy, University of Pittsburgh, Pittsburgh, PA, USA.
UPMC Hillman Cancer Center · USLake Erie College of Osteopathic Medicine · USUniversity of Pittsburgh · US

Funding

Therapuetic Immune Targeting of EphA2 Expressed by Melanoma & Its Tumor-AssociateP50CA121973 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIRKWOOD, JOHN MUNN · 2008 to 2018
$22.9M
Targeting the Chemokine System to Sensitize Tumors to ImmunotherapyP01CA234212 · NCI · ROSWELL PARK CANCER INSTITUTE CORP · PI KALINSKI, PAWEL · 2020 to 2024
$10.1M
Image guided immunotherapy and targeted radionuclide therapy of metastatic melanomaR01CA214018 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI ANDERSON, CAROLYN J. · 2017 to 2021
$2.3M
World Molecular Imaging Congress. The WMIC provides a platform for a wide array of scientists and clinicians with diverse areas of expertise to interact, present, and discuss cutting-edge advances inR13EB033695 · NIBIB · WORLD MOLECULAR IMAGING SOCIETY · PI ANDERSON, CAROLYN J. · 2022 to 2022
$14k
NCI NIH HHS P01 CA234212NCI NIH HHS P50 CA121973NCI NIH HHS R01 CA214018NIBIB NIH HHS R13 EB033695
6 · The paper itself

Abstract

We describe the development, optimization, and validation of 384-well growth inhibition assays for six patient-derived melanoma cell lines (PDMCLs), three wild type (WT) for

Indexed as

AnimalsAntineoplastic AgentsCell Line, TumorDose-Response Relationship, DrugDrug Resistance, NeoplasmDrug Screening Assays, AntitumorDrug SynergismHigh-Throughput Screening AssaysHumansMelanomaMiceReproducibility of ResultsAntineoplastic Agentsapoptosiscancer drug resistancedrug combinationsmelanomasynergy

Identifiers

PMID33208016
PMCPMC8128935
OpenAlexW3098065629

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.